OTCMKTS:ACUR Acura Pharmaceuticals (ACUR) Stock Price, News & Analysis $0.0004 0.00 (0.00%) As of 10/6/2025 Add Compare Share Share Stock Analysis Stock AnalysisChartSEC FilingsShort InterestBuy This Stock About Acura Pharmaceuticals Stock (OTCMKTS:ACUR) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Acura Pharmaceuticals alerts:Sign Up Key Stats Today's Range$0.0004▼$0.000450-Day Range N/A52-Week Range$0.00▼$0.75VolumeN/AAverage Volume3,501 shsMarket Capitalization$26.60 thousandP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Acura Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products designed to deter prescription drug abuse and misuse. The company’s core business centers on proprietary drug formulations that incorporate its Aversion and ARCUS® abuse-deterrent technologies. These platforms are intended to make it more difficult to tamper with or extract active pharmaceutical ingredients from oral dosage forms, helping to address public health concerns around opioid and stimulant abuse. Acura’s lead product, Oxaydo®, is an immediate‐release oxycodone tablet that employs Aversion® technology to discourage tampering and intravenous abuse. In addition to Oxaydo®, the company has advanced a pipeline of collaborative research agreements with other pharmaceutical partners seeking to integrate Acura’s intellectual property into their own opioid and stimulant portfolios. Acura’s ARCUS® technology further expands its offerings by providing a nasal discomfort mechanism designed to deter intranasal abuse of solid dosage forms. Founded in 2001 and headquartered in Palatine, Illinois, Acura Pharmaceuticals serves markets across the United States and has established licensing relationships with both branded and generic drug manufacturers. The company operates under the leadership of an executive team with experience in pharmaceutical development, regulatory affairs and commercial strategy. Acura continues to pursue regulatory approvals, strategic collaborations and intellectual property development aimed at reducing the societal impact of prescription drug abuse.AI Generated. May Contain Errors. Read More Receive ACUR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Acura Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ACUR Stock News HeadlinesReviewing Acura Pharmaceuticals (OTCMKTS:ACUR) & Taysha Gene Therapies (NASDAQ:TSHA)September 28, 2025 | americanbankingnews.comAcura Pharmaceuticals Secures Loan Amid Financial StrugglesSeptember 4, 2025 | tipranks.comTilson: “I’m watching HOOD”A strange chasm is coming to Wall Street... It's already creating millionaires and billionaires at the fastest pace in history. CNBC calls it "the largest wealth creation spree in history." Yet 1 in 3 Americans now fear their financial situation is deteriorating. There's only one way to survive, says the man who predicted 2008 and 2020, but sadly it's already too late for many.October 7 at 2:00 AM | Stansberry Research (Ad)Acura Pharmaceuticals Delays Quarterly Report FilingAugust 19, 2025 | tipranks.comAcura Pharmaceuticals Receives $200,000 Loan BoostJuly 21, 2025 | tipranks.comAcura Pharma Stock Price History - Investing.comJuly 2, 2025 | investing.comAcura Pharmaceuticals, Inc. (ACUR) - Yahoo FinanceJuly 2, 2025 | finance.yahoo.comAcura Pharmaceuticals Faces Financial Challenges Amid New LoansJune 24, 2025 | tipranks.comSee More Headlines ACUR Stock Analysis - Frequently Asked Questions How have ACUR shares performed this year? Acura Pharmaceuticals' stock was trading at $0.0002 at the start of the year. Since then, ACUR shares have increased by 100.0% and is now trading at $0.0004. How were Acura Pharmaceuticals' earnings last quarter? Acura Pharmaceuticals, Inc. (OTCMKTS:ACUR) announced its quarterly earnings data on Friday, February, 28th. The specialty pharmaceutical company reported $0.00 EPS for the quarter. The specialty pharmaceutical company had revenue of $1.32 million for the quarter. Does Acura Pharmaceuticals have any subsidiaries? Acura Pharmaceuticals subsidiaries include Acura Pharmaceutical Technologies Inc.. How do I buy shares of Acura Pharmaceuticals? Shares of ACUR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Acura Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Acura Pharmaceuticals investors own include Denali Therapeutics (DNLI), Ekso Bionics (EKSO), Matinas Biopharma (MTNB), VIVUS (VVUS), Corbus Pharmaceuticals (CRBP), Fulcrum Therapeutics (FULC) and Adamis Pharmaceuticals (ADMP). Company Calendar Last Earnings2/28/2020Today10/07/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry MED - GENERIC DRG Sub-IndustryPharmaceuticals Current SymbolOTCMKTS:ACUR Previous SymbolNASDAQ:ACUR CIK786947 Webwww.acurapharm.com Phone(847) 705-7709Fax847-705-5399Employees10Year Founded1935Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares66,500,000Free Float53,066,000Market Cap$26.60 thousand OptionableNot Optionable Beta-2.44 Social Links 7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (OTCMKTS:ACUR) was last updated on 10/7/2025 by MarketBeat.com Staff From Our PartnersMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredU.S. Government Sparking Crypto RallyU.S. Puts GDP on the Blockchain Could this spark the next crypto supercycle? Discover the altcoins poised t...Crypto 101 Media | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acura Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Acura Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.